Adjuvant Chemotherapy Is Not Guided by Pathologic Treatment Effect After Neoadjuvant Chemotherapy in Pancreatic Cancer.
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
22
3
2022
Statut:
ppublish
Résumé
Currently, there is no guidance for optimal adjuvant chemotherapy selection after pancreatectomy with a partial or poor response to neoadjuvant therapy. This study seeks to describe an institution's practice patterns of adjuvant chemotherapy selection after neoadjuvant therapy. Patients at a single institution receiving neoadjuvant chemotherapy followed by pancreatectomy for pancreatic cancer were reviewed. Patients enrolled in trials or without follow-up were excluded. Types of chemotherapy, the College of American Pathologists pathologic tumor response, and medical oncology plans were recorded. Forty-one patients met inclusion criteria. Pathologic review of treatment effect demonstrated that 3 patients (7.3%) had complete pathologic response, 3 (7.3%) had near complete pathologic response, 16 (39%) had partial response, and 14 (34.1%) had poor/no response to neoadjuvant chemotherapy. Fourteen of the 30 patients with partial or poor response (46.7%) received an alternate adjuvant regimen. Pathologic response to neoadjuvant chemotherapy specifically guided therapy in 11 (30.5%) patients. Despite 73.1% of patients with partial or poor response to neoadjuvant chemotherapy, only 46.7% received a different adjuvant regimen. Medical oncologists infrequently considered treatment effect when choosing adjuvant therapy. Pathologic response to neoadjuvant chemotherapy should be considered when selecting adjuvant chemotherapy.
Identifiants
pubmed: 34714279
doi: 10.1097/MPA.0000000000001881
pii: 00006676-202109000-00005
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1163-1168Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Crane CH, Varadhachary G, Wolff RA, et al. The argument for preoperative chemoradiation for localized, radiographically resectable pancreatic cancer. Best Pract Res Clin Gastroenterol . 2006;20:365–382.
Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol . 1997;15:928–937.
Dhir M, Malhotra GK, Sohal DPS, et al. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol . 2017;15:183.
Eguchi H, Takeda Y, Takahashi H, et al. A prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol . 2019;26:4498–4505.
Motoi F, Kosuge T, Ueno H, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol . 2019;49:190–194.
Sharma G, Whang EE, Ruan DT, et al. Efficacy of neoadjuvant versus adjuvant therapy for resectable pancreatic adenocarcinoma: a decision analysis. Ann Surg Oncol . 2015;22 Suppl 3:S1229–S1237.
National Library of Medicine (US). Identifier NCT03977233, Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer. 2019. Available at: https://clinicaltrials.gov/ct2/show/NCT03977233?cond=Pancreatic+Ductal+Adenocarcinoma&cntry=US&phase=1&draw=3&rank=29 . Accessed September 22, 2019.
Beane JD, Borrebach JD, Zureikat AH, et al. Optimal pancreatic surgery: are we making progress in North America? Ann Surg . 2021;274:e355–e363.
He J, Blair AB, Groot VP, et al. Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer? Ann Surg . 2018;268:1–8.
Macedo FI, Ryon E, Maithel SK, et al. Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nab-paclitaxel chemotherapy in resected pancreatic cancer. Ann Surg . 2019;270:400–413.
Kakar S, Shi C, Adsay NV, et al. Protocol for the Examination of Specimens From Patients With Carcinoma of the Pancreas. June 2017. Version 4.0.0.1. Available at: https://documents.cap.org/protocols/cp-gihepatobiliary-pancreas-exocrine-17protocol-4001.pdf . Accessed February 27, 2020.
Perri G, Prakash L, Qiao W, et al. Postoperative chemotherapy benefits patients who received preoperative therapy and pancreatectomy for pancreatic adenocarcinoma. Ann Surg . 2020;271:996–1002.
de Geus SWL, Kasumova GG, Eskander MF, et al. Is neoadjuvant therapy sufficient in resected pancreatic cancer patients? A national study. J Gastrointest Surg . 2018;22:214–225.
Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma version 1.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN . 2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic_blocks.pdf . Accessed February 27, 2020.
Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO Clinical Practice Guideline Update. J Clin Oncol . 2019;37:2082–2088.
Perri G, Prakash L, Wang H, et al. Radiographic and serologic predictors of pathologic major response to preoperative therapy for pancreatic cancer. Ann Surg . 2021;273:806–813.
Katz MH, Varadhachary GR, Fleming JB, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol . 2010;17:1794–1801.
Humphris JL, Chang DK, Johns AL, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol . 2012;23:1713–1722.
Wei T, Zhang Q, Li X, et al. Monitoring tumor burden in response to FOLFIRINOX chemotherapy via profiling circulating cell-free DNA in pancreatic cancer. Mol Cancer Ther . 2019;18:196–203.
Groot VP, Mosier S, Javed AA, et al. Circulating tumor DNA as a clinical test in resected pancreatic cancer. Clin Cancer Res . 2019;25:4973–4984.
Krantz BA, O'Reilly EM. Biomarker-based therapy in pancreatic ductal adenocarcinoma: an emerging reality? Clin Cancer Res . 2018;24:2241–2250.
Lowery MA, Jordan EJ, Basturk O, et al. Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype. Clin Cancer Res . 2017;23:6094–6100.
Tesfaye AA, Wang H, Hartley ML, et al. A pilot trial of molecularly tailored therapy for patients with metastatic pancreatic ductal adenocarcinoma. J Pancreat Cancer . 2019;5:12–21.
Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol . 2020;21:508–518.